ArticleMolecular imaging and biology2013
A comparative study of primary and recurrent human glioblastoma multiforme using the small animal imaging and molecular expressive profiles.
Article in Molecular imaging and biology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 9 citations in OpenAlex.
- Strategic Decoy Peptides Interfere with MSI1/AGO2 Interaction to Elicit Tumor Suppression Effects.Cancers · 2022Article
- Up-regulation of cofilin-1 in cell senescence associates with morphological change and p27Aging cell · 2021Article
- Arsenic trioxide-mediated suppression of miR-182-5p is associated with potent anti-oxidant effects through up-regulation ofOncotarget · 2018Article
- Involvement of let-7 microRNA for the therapeutic effects of Rhenium-188-embedded liposomal nanoparticles on orthotopic human head and neck cancer model.Oncotarget · 2016Article
- Musashi-1 regulates AKT-derived IL-6 autocrinal/paracrinal malignancy and chemoresistance in glioblastoma.Oncotarget · 2016Article
- Progranulin promotes Temozolomide resistance of glioblastoma by orchestrating DNA repair and tumor stemness.Oncogene · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeGlioblastoma multiforme (GBM) is the most malignant brain tumor with the characteristics of highly infiltrative growth and recurrent rate. In this study, we used animal imaging and molecular expressive profiles to investigate the characteristics of the primary tumor (GBM-3) cells and recurrent tumor (S1R1) cells from different GBM patients. PROCEDURES: Bioluminescent imaging and 3T magnetic resonance imaging (MRI) were used for assessing the orthotopical tumor development of GBM cells harboring a polycistronic reporter gene system. Western blot analysis and quantitative polymerase chain reaction were used to compare the molecular expressive profiles of two types of GBM cells.
resultsS1R1 cells exhibited apparent invasive ability compared to GBM-3 cells using in vitro invasion assay. In vivo bioluminescent imaging showed that intracranial tumors are formed by both types of GBM cells, but the bioluminescent signal was also detected in the lumbar region at late-stage tumor formed by S1R1 cells. The MRI showed that intracranial tumors formed by S1R1 cells were highly infiltrative compared to that formed by GBM-3 cells. Additionally, these two GBM types expressed different patterns of molecules associated with tumor development. Moreover, the suppressive effects of interleukine-23 (IL-23) on xenograft tumors formed by both GBM types were detected using bioluminescent imaging.
conclusionThe current data suggest that the in vivo growth behaviors and therapeutic responses of the primary and recurrent human GBMs were comparable using the reporter gene imaging, and different molecular expressive profiles exist between these two GBM types.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.